Company Profile
Neptune Medical is a US-based manufacturer of gastrointestinal endoscopy devices and robotic systems, headquartered in Burlingame, California, USA. Founded in 2016 by Alex Tilson, the company operates as an independent private entity, serving global gastroenterology markets with approximately 67 employees and strategic backing from Olympus Corporation of the Americas.
Core Products ＆ Technologies
Endoscopy Access ＆ Robotics
• Pathfinder Endoscope Overtube with Balloon Device: FDA 510(k) cleared (K230801, July 28, 2023) endoscopic access overtube for gastroenterology-urology procedures, enabling enhanced scope stability and therapeutic access
• Triton Medical Robotic System: GI robotic platform for diagnostic colonoscopy, endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD); CARE 1 first-in-human study demonstrated 100% cecal intubation, 67.5% polyp detection rate, 54.2% adenoma detection rate, and zero adverse events in 50 adults; not yet authorized for commercial sale
• Dynamic Rigidization™ Technology: Proprietary platform technology instantly toggling thin-walled tubes between flexible and rigid states for enhanced procedural control
Market Position ＆ Certifications
Neptune Medical holds an emerging innovator position in the GI endoscopy robotics and access devices market, competing with Medtronic and Boston Scientific in advanced endoscopy platforms. Key strengths include:
• 10 years of US medical device innovation heritage since founding
• Regulatory milestones: FDA 510(k) cleared Pathfinder overtube (K230801, 2023); Triton system not yet authorized for commercial sale pending further clinical development
• Clinical validation: CARE 1 study presented at Digestive Disease Week 2026 showed favorable ergonomics, 100% cecal intubation, and high-quality colonoscopy performance
• Strategic backing: $97M Series D financing (August 2024) led by Sonder Capital and Olympus Corporation of the Americas
• Leadership: Board chaired by medical robotics pioneer Dr. Fred Moll (appointed November 2023)
Corporate Timeline
2016 — Founded in Burlingame, California, USA
2023 — Pathfinder Endoscope Overtube received FDA 510(k) clearance (K230801, July); Dr. Fred Moll appointed Chairman of the Board (November)
2024 — Closed $97M Series D financing (August); spun out Jupiter Endovascular subsidiary
2026 — Presented CARE 1 first-in-human study results at Digestive Disease Week (May), demonstrating 100% cecal intubation, 67.5% polyp detection rate, and 54.2% adenoma detection rate
Target Markets ＆ Applications
• Diagnostic Colonoscopy: Triton robotic system for screening, surveillance, and diagnostic colonoscopy with enhanced polyp detection
• Endoscopic Therapeutics: Pathfinder overtube and Triton platform for EMR and ESD procedures in the lower GI tract
• Endoscopy Access: Pathfinder balloon overtube for stabilizing endoscopes during complex therapeutic interventions
Contact Information
Global Headquarters
Address: 1828 El Camino Real, Suite 508, Burlingame, CA 94010, USA
Telephone: (888) 202-8401
Email: info@neptunemedical.com
Corporate Status
Entity Type: Independent Private Company (No Parent Company)
Stock: Not Publicly Traded
Website: neptunemedical.com
